Titlebook: Clinical Applications of Immunotoxins; Arthur E. Frankel (Associate Professor of Medicine Book 1998 The Editor(s) (if applicable) and The

名字的误用

Clinical Trials with Blocked Ricin Immunotoxins,of malignancy in the majority of patients. Furthermore, substantial morbidity and potential mortality is associated with the use of these aggressive treatment programs. New anti-tumor agents ideally should circumvent the two major limitations of current therapy: devastating nonspecific side effects and tumor cell resistance.

灯丝

Glower

T. E. Cooke,J. Matatko,D. C. Stafford as growth factors or monoclonal antibodies, can be linked to protein toxins by random chemical modification of lysine or sulfhydral residues (. et al. 1987) or by fusion of the new protein domains at the COOH- or NH.-terminal of the protein by molecular biology techniques (. et al. 1986).

全等

Immunotoxins for Brain Tumor Therapy, as growth factors or monoclonal antibodies, can be linked to protein toxins by random chemical modification of lysine or sulfhydral residues (. et al. 1987) or by fusion of the new protein domains at the COOH- or NH.-terminal of the protein by molecular biology techniques (. et al. 1986).

拾落穗

Jocelyn Spence,Stuart Andrews,David Frohlichften linked to radioisotopes or toxins to increase their toxicity. Immunotoxins (ITs) are constructed by chemically or genetically linking the antibody moiety to a potent bacterial or plant toxin. To date, the most widely used toxin is ricin, which is derived from the seeds of . (castor bean).

hieroglyphic

刺穿

漂浮

Jocelyn Spence,Stuart Andrews,David Frohlichins that act catalytically to kill cells, bacterial and plant toxins are often employed as the cell-killing component of immunotoxins. Here we provide background information into the structure-function relationships of toxins and discuss how they can be combined with cell-binding antibodies or other ligands to generate immunotoxins.

有斑点

Introduction,ins that act catalytically to kill cells, bacterial and plant toxins are often employed as the cell-killing component of immunotoxins. Here we provide background information into the structure-function relationships of toxins and discuss how they can be combined with cell-binding antibodies or other ligands to generate immunotoxins.

AGATE

Book 1998 . . . . . . . . . . . . . . . . . . . . 2 2. 2 Binding. . . . . . . . . . . . . . . . . . . . . . . . . 3 3 Intracellular Processing - Cleavage and Reduction . . . . . . 4 3. 1 Cytosolic Activity . . . . . . . . . . . . . . . . 5 4 Immunotoxin Design and Testing. 6 5 Conclusion. . 8 References. . .